CB-154 mesylate
CB-154 mesylate structure
|
Common Name | CB-154 mesylate | ||
|---|---|---|---|---|
| CAS Number | 22260-51-1 | Molecular Weight | 750.700 | |
| Density | N/A | Boiling Point | 891.3ºC at 760 mmHg | |
| Molecular Formula | C33H44BrN5O8S | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 492.8ºC | |
| Symbol |
GHS07, GHS09 |
Signal Word | Warning | |
|
Dopamine-2 receptor activation suppresses PACAP expression in gonadotrophs.
Endocrinology 155(7) , 2647-57, (2014) Pituitary adenylate cyclase-activating polypeptide (PACAP) is expressed at a high level in the fetal pituitary and decreases profoundly between embryonic day 19 and postnatal day 1 (PN1), with a further decrease from PN1 to PN4. In this series of experiments,... |
|
|
Does bromocriptine play a role in decreasing oxidative stress for early weaned programmed obesity?
Life Sci. 95(1) , 14-21, (2014) Studies have demonstrated that early weaning can promote metabolic syndrome during adulthood and that obesity increases oxidative stress. Thus, we aimed to evaluate redox status in a pharmacological early weaning rodent model programmed for metabolic syndrome... |
|
|
Mediation of dopamine D2 receptors activation in post-conditioning-attenuated cardiomyocyte apoptosis
Exp. Cell Res. 323(1) , 118-30, (2014) The physiological and pathological roles of dopamine D2 receptors (DR2) in the regulation of cardiovacular functions have been recognized. DR2 activation protects hypoxia/reoxygenation (H/R)-induced cardiomyocyte injury and apoptosis, and ischemic post-condit... |
|
|
Combined low calcium and lack magnesium is a risk factor for motor deficit in mice.
Biosci. Biotechnol. Biochem. 77(2) , 266-70, (2013) The populations of the Kii Peninsula in Japan and of Guam present high incidences of amyotrophic lateral sclerosis and Parkinsonism-dementia complex. It is thought that low levels of calcium (Ca) and magnesium (Mg) in the drinking water are involved in the pa... |
|
|
Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.
J. Am. Heart Assoc. 1(5) , e002279, (2012) Bromocriptine-QR (a quick-release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, is a US Food and Drug Administrration-approved treatment for type 2 diabetes mellitus (T2DM). A 3070-subject randomized trial demonstrated a significant,... |
|
|
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Intern. Med. 52(3) , 325-32, (2013) The long-term use of levodopa to treat Parkinson's disease (PD) is often limited by the development of motor complications (e.g., levodopa-induced dyskinesia, LID). We hypothesized that a non-ergot dopamine agonist with strong affinity for D3) dopamine recept... |
|
|
[Drug therapy for acromegaly].
Orv. Hetil. 154(39) , 1527-34, (2013) Prolonged overproduction of growth hormone, like insulin-like growth factor-1 hypersecretion leads to acromegaly in adults. This is associated with several co-morbidities and increased mortality. Despite typical clinical features and modern diagnostic tools, ... |
|
|
The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations.
Endocr. Pract. 19(1) , 100-6, (2013) To review available data on the efficacy and safety of bromocriptine-QR (BQR) and to consider its role in the management of Type 2 diabetes mellitus (T2DM).Published literature reporting the efficacy and safety of BQR in the treatment of T2DM was reviewed, in... |
|
|
Galectin-1 and galectin-3 in the corpus luteum of mice are differentially regulated by prolactin and prostaglandin F2α.
Reproduction 144(5) , 617-24, (2012) Galectin-1 and galectin-3, β-galactoside-binding lectins, are specifically expressed in the regressing corpus luteum (CL) of mice; however, their function remains unclear. In this study, we examined the effects of prolactin (PRL) and prostaglandin F(2) (α) (P... |
|
|
Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents.
Endocr. Pract. 18(6) , 931-43, (2012) To investigate the effect of Bromocriptine-QR on glycemic control in patients with type 2 diabetes whose glycemia is poorly controlled on one or two oral anti-diabetes agents.Five hundred fifteen Type 2 Diabetes Mellitus (T2DM) subjects (ages 18 to 80 and ave... |